Genes conferring drug resistance can potentially be applied clinically in two different ways: (a) To confer drug-resistance upon normal, sensitive tissues, thereby averting toxic side-effects and allowing improved anti tumor chemotherapy; (h)To allow selective, in vivo expansion of cells engineered to express the drug resistance gene, perhaps along with other therapeutic genes. In this competing renewal application, experiments are described which will continue to address the use of methotrexate (MTX) as an anti-tumor or selective agent in combination with variant forms of drug- resistant dihydrofolate reductase (DHFR). There are three Specific Aims.
In Aim 1, the mechanism by which drug-resistant DHFR gene expression may be used for improved chemotherapy will be addressed, by characterizing lympho-hematopoietic cell types which repopulate the intestine after transplantation of DHFR transgenic marrow and which may contribute to MTX resistance in the GI tract. These studies will also contribute to a greater understanding of the role of lymphohematopoietic cells in the maintenance of GI structure and function, especially in patients undergoing BMT and/or chemotherapy.
In Aim 2, experiments will be conducted to determine the extent to which drug resistance conferred by transplantation with MTX-resistant DHFR transgenic marrow will allow improved survival of animals bearing the well-characterized L1210 and P388 model leukemias by administration of higher doses of MTX. MTX- mediated selective enrichment of drug-resistant DHFR expressing marrow will be tested directly in Aim 3 through competitive marrow recovery experiments in which animals transplanted with mixtures of normal and DHFR transgenic marrow will be allowed to engraft, and then administered combinations of antifolate (MTX, trimetrexate) with nucleoside transport inhibitor to prevent nucleic acid precursor salvage and circumvention of antifolate toxicity. Dosing regimens will be optimized, and the extent to which low levels of engrafted drug-resistant stem cells can be expanded will be determined. Results from these studies will address the feasibility of applying MTX resistance gene transfer for improved chemotherapy in humans as well as using MTX as an in vivo selective agent to deal with the low levels of gene transfer currently observed in humans and in large animals models, thus contributing a crucial preclinical component to the ongoing formulation of DHFR gene transfer clinical trials at the University of Minnesota.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Project (R01)
Project #
Application #
Study Section
Experimental Therapeutics Subcommittee 1 (ET)
Program Officer
Wolpert, Mary K
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Minnesota Twin Cities
Schools of Medicine
United States
Zip Code
Gori, Jennifer L; Beard, Brian C; Williams, Nathaniel P et al. (2013) In vivo protection of activated Tyr22-dihydrofolate reductase gene-modified canine T lymphocytes from methotrexate. J Gene Med 15:233-41
Gori, J L; Tian, X; Swanson, D et al. (2010) In vivo selection of human embryonic stem cell-derived cells expressing methotrexate-resistant dihydrofolate reductase. Gene Ther 17:238-49
Gori, Jennifer L; Podetz-Pedersen, Kelly; Swanson, Debra et al. (2007) Protection of mice from methotrexate toxicity by ex vivo transduction using lentivirus vectors expressing drug-resistant dihydrofolate reductase. J Pharmacol Exp Ther 322:989-97
Belur, Lalitha R; James, Rohaizah I; May, Chad et al. (2005) Methotrexate preconditioning allows sufficient engraftment to confer drug resistance in mice transplanted with marrow expressing drug-resistant dihydrofolate reductase activity. J Pharmacol Exp Ther 314:668-74
Sweeney, Colin L; Frandsen, Joel L; Verfaillie, Catherine M et al. (2003) Trimetrexate inhibits progression of the murine 32Dp210 model of chronic myeloid leukemia in animals expressing drug-resistant dihydrofolate reductase. Cancer Res 63:1304-10
Carlson, Jonathan C T; Kanter, Aaron; Thuduppathy, Guruvasuthevan R et al. (2003) Designing protein dimerizers: the importance of ligand conformational equilibria. J Am Chem Soc 125:1501-7
Pineda, Pamela; Kanter, Aaron; McIvor, R Scott et al. (2003) Dihydrofolate reductase mutant with exceptional resistance to methotrexate but not to trimetrexate. J Med Chem 46:2816-8
Warlick, Christopher A; Diers, Michaeleen D; Wagner, John E et al. (2002) In vivo selection of antifolate-resistant transgenic hematopoietic stem cells in a murine bone marrow transplant model. J Pharmacol Exp Ther 300:50-6
Sweeney, Colin L; Diers, Miechaleen D; Frandsen, Joel L et al. (2002) Methotrexate exacerbates tumor progression in a murine model of chronic myeloid leukemia. J Pharmacol Exp Ther 300:1075-84
Belur, L R; Boelk-Galvan, D; Diers, M D et al. (2001) Methotrexate accumulates to similar levels in animals transplanted with normal versus drug-resistant transgenic marrow. Cancer Res 61:1522-6

Showing the most recent 10 out of 19 publications